within Pharmacolibrary.Drugs.ATC.D;

model D10AX02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.5e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D10AX02</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Resorcinol is a dihydroxy benzene compound used topically in dermatology for its keratolytic and antiseptic properties. It is included in combination acne medications and has been used for other skin conditions such as eczema, psoriasis, and seborrheic dermatitis. Resorcinol is not used systemically and its topical use is less common today due to the development of newer medications; products containing resorcinol remain available over-the-counter in some formulations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for systemic absorption in adult humans after dermal application, as direct PK studies in humans are not available.</p><h4>References</h4><ol><li><p>Bissonnette, R, Stein Gold, L, Rubenstein, DS, Tallman, AM, &amp; Armstrong, A (2021). Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. <i>Journal of the American Academy of Dermatology</i> 84(4) 1059–1067. DOI:<a href=&quot;https://doi.org/10.1016/j.jaad.2020.10.085&quot;>10.1016/j.jaad.2020.10.085</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33157177/&quot;>https://pubmed.ncbi.nlm.nih.gov/33157177</a></p></li><li><p>Silverberg, JI, Boguniewicz, M, Quintana, FJ, Clark, RA, Gross, L, Hirano, I, Tallman, AM, Brown, PM, Fredericks, D, Rubenstein, DS, &amp; McHale, KA (2024). Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. <i>The Journal of allergy and clinical immunology</i> 154(1) 1–10. DOI:<a href=&quot;https://doi.org/10.1016/j.jaci.2023.12.013&quot;>10.1016/j.jaci.2023.12.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38154665/&quot;>https://pubmed.ncbi.nlm.nih.gov/38154665</a></p></li><li><p>Zhang, Y, Sil, BC, Kung, CP, Hadgraft, J, Heinrich, M, Sinko, B, &amp; Lane, ME (2019). Characterization and topical delivery of phenylethyl resorcinol. <i>International journal of cosmetic science</i> 41(5) 479–488. DOI:<a href=&quot;https://doi.org/10.1111/ics.12565&quot;>10.1111/ics.12565</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31378949/&quot;>https://pubmed.ncbi.nlm.nih.gov/31378949</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D10AX02;
